These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22543528)

  • 1. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.
    Schettini J; Kidiyoor A; Besmer DM; Tinder TL; Roy LD; Lustgarten J; Gendler SJ; Mukherjee P
    Cancer Immunol Immunother; 2012 Nov; 61(11):2055-65. PubMed ID: 22543528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
    Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
    Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
    Roda JM; Parihar R; Carson WE
    J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
    van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
    Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer.
    Jahrsdörfer B; Weiner GJ
    Semin Oncol; 2003 Aug; 30(4):476-82. PubMed ID: 12939716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
    Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
    J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma.
    Warren TL; Dahle CE; Weiner GJ
    Clin Lymphoma; 2000 Jun; 1(1):57-61. PubMed ID: 11707814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
    Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
    Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.
    Alderson KL; Luangrath M; Elsenheimer MM; Gillies SD; Navid F; Rakhmilevich AL; Sondel PM
    Cancer Immunol Immunother; 2013 Apr; 62(4):665-75. PubMed ID: 23151945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.
    Garbi N; Arnold B; Gordon S; Hämmerling GJ; Ganss R
    J Immunol; 2004 May; 172(10):5861-9. PubMed ID: 15128765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of natural killer-like YT-INDY cells by oligodeoxynucleotides and binding by homologous pattern recognition proteins.
    Kaur H; Jaso-Friedmann L; Leary JH; Praveen K; Brahmi Z; Evans DL
    Scand J Immunol; 2005 Oct; 62(4):361-70. PubMed ID: 16253123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-21 enhances NK cell activation in response to antibody-coated targets.
    Roda JM; Parihar R; Lehman A; Mani A; Tridandapani S; Carson WE
    J Immunol; 2006 Jul; 177(1):120-9. PubMed ID: 16785506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells.
    Sivori S; Carlomagno S; Moretta L; Moretta A
    Eur J Immunol; 2006 Apr; 36(4):961-7. PubMed ID: 16525994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
    Wang SY; Racila E; Taylor RP; Weiner GJ
    Blood; 2008 Feb; 111(3):1456-63. PubMed ID: 18024795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
    Wooldridge JE; Ballas Z; Krieg AM; Weiner GJ
    Blood; 1997 Apr; 89(8):2994-8. PubMed ID: 9108420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta.
    Rothenfusser S; Hornung V; Krug A; Towarowski A; Krieg AM; Endres S; Hartmann G
    Eur J Immunol; 2001 Dec; 31(12):3525-34. PubMed ID: 11745372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.